Forest Laboratories sees improved sales in second quarter

21 July 2010 00:00 in Pharmaceutical Company Financials


Forest Laboratories has seen a year-on-year growth in sales during the second quarter of 2010 thanks to the strong performance of several key products.

According to data from the firm's latest financial report, net sales grew by 7.6 per cent from Q2 2009 to reach $1.02 billion (667.9 million pounds), with products such as Namenda and Bystolic seeing double-digit growth.

The firm also highlighted improving sales of its newest drug, the fibromyalgia treatment Savella, which was launched in April 2009.

Howard Solomon, chairman and chief executive officer of Forest, also hailed the advancement of several compounds to phase II and III testing in the last quarter, in addition to its collaboration with TransTech Pharma on a new diabetes drug.

He said: "The TransTech programme may offer a unique new therapeutic option for the millions of patients who suffer from diabetes and we look forward to advancing it through development."

Among the treatments which Forest is currently developing are aclidinium bromide and LAS100977, two respiratory disease therapies on which it has collaborated with Almirall.

Other news stories from 21/07/2010

• Forest Laboratories sees improved sales in second quarter
• Actelion negotiates option to acquire Trophos
• Gilead Sciences experiences double-digit Q2 growth
• Biogen Idec hails 'solid' second quarter performance
• Slimming supplements 'do not tackle root cause of obesity'
• Cook Medical BIGopsy forceps show benefits in studies
• Elemental Healthcare to launch incisionless weight loss surgery in UK
• Reckitt Benckiser offers to purchase SSL International
• Millward Brown confirms new neuroscience team members
• Merial and Biolex to collaborate on vaccine development
• Inverness Medical Innovations completes rebranding to Alere
• Roche and Exiqon to ally on PCR product marketing

Related news

• Forest Laboratories and Trevena to co-develop heart failure drug
• Forest Laboratories and Almirall report positive COPD trial data
• Forest Laboratories and Almirall report positive COPD drug data
• Forest Laboratories and Glenmark agree inflammatory disease alliance
• Forest Laboratories UK implements Cegedim CRM solution

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency

Feedback | News Archive | Browse News | Hotels | Links | Browse Jobs | Legal Notice | Privacy Policy

© Copyright 2013 Zenopa Ltd